Medically reviewed by a licensed healthcare professional. Last updated March 2026.
Understanding Wegovy's 5-Step Dose Escalation
Wegovy (semaglutide 2.4 mg) is the only semaglutide formulation specifically FDA-approved for chronic weight management. Unlike Ozempic, which tops out at 2.0 mg, Wegovy uses a deliberate 5-step escalation over 16 to 20 weeks to reach its full 2.4 mg maintenance dose.
- Wegovy's 5-step titration takes 16 to 20 weeks, escalating from 0.25 mg to the 2.4 mg maintenance dose in 4-week intervals.
- The STEP 1 trial showed an average 14.9% body weight loss at 68 weeks on the 2.4 mg maintenance dose.
- Nausea affected about 44% of patients overall, but typically peaked within the first 1 to 2 weeks at each new dose and then subsided.
- Patients who cannot tolerate 2.4 mg may stay at 1.7 mg long-term, as some achieve strong results without reaching the maximum dose.
This slow titration is not optional. It exists because jumping straight to 2.4 mg would cause severe nausea, vomiting, and diarrhea in most patients. The gradual increase gives your GLP-1 receptors time to adapt, significantly reducing the intensity and duration of side effects.
Complete Wegovy Dosing Table
| Step | Dose | Weeks | Duration |
|---|---|---|---|
| 1 | 0.25 mg weekly | Weeks 1 to 4 | 4 weeks |
| 2 | 0.5 mg weekly | Weeks 5 to 8 | 4 weeks |
| 3 | 1.0 mg weekly | Weeks 9 to 12 | 4 weeks |
| 4 | 1.7 mg weekly | Weeks 13 to 16 | 4 weeks |
| 5 (Maintenance) | 2.4 mg weekly | Week 17 onward | Ongoing |
The FDA-approved dosing schedule escalates semaglutide in four 4-week steps, beginning at 0.25 mg and reaching the 2.4 mg maintenance dose at week 17[1]. Each step uses its own dedicated single-dose pen[2]. You cannot adjust the dose on a Wegovy pen the way you can with Ozempic's multi-dose pens. When your provider writes a new prescription for the next step, your pharmacy will dispense the corresponding pen strength.
Why the Slow Titration Matters
The gradual escalation is not just about comfort. It directly affects whether you stay on the medication long-term:
Reduced dropout rates. Clinical trials showed that patients who followed the escalation schedule were significantly more likely to remain on the medication at 68 weeks compared to those who experienced early, severe side effects.
Better tolerability. In the STEP trials, nausea occurred in about 44% of patients overall, but was mostly mild to moderate and transient[3]. Patients who followed the titration schedule reported that nausea typically peaked during the first 1 to 2 weeks at each new dose and then subsided.
Consistent absorption. Giving your body four weeks at each dose allows semaglutide to reach steady-state blood levels before increasing again. This produces a smoother pharmacokinetic profile and more predictable effects.
What to Expect at Each Dose
Step 1: 0.25 mg (Weeks 1 to 4)
This introductory dose is sub-therapeutic for weight loss. Its sole purpose is to let your gastrointestinal system adjust to semaglutide. You may notice:
- Mild appetite reduction, often described as simply not thinking about food as much
- Possible mild nausea in the first 2 to 3 days after your initial injection
- Minimal weight change, perhaps 1 to 3 pounds from naturally eating a bit less
- Some patients feel nothing at this dose, and that is completely normal
Step 2: 0.5 mg (Weeks 5 to 8)
The first dose with noticeable therapeutic effect. Most patients begin to experience real appetite suppression here:
- Portions feel more satisfying. You may leave food on your plate for the first time
- Weight loss typically begins in earnest, around 1 pound per week
- Nausea may briefly return after the dose increase, usually for 2 to 5 days
- "Food noise" diminishes. Cravings, especially for sugary and high-fat foods, often decrease
Step 3: 1.0 mg (Weeks 9 to 12)
A meaningful step up. Many patients describe this as the dose where everything clicks:
- Consistent weight loss of 1 to 2 pounds per week is common
- Appetite suppression is pronounced. Meals that once felt normal now feel large
- GI side effects from the transition usually resolve within a week
- Some patients experience constipation at this dose. Increasing fiber and water intake helps
- By the end of this phase, most patients have lost 8 to 12 pounds total
Step 4: 1.7 mg (Weeks 13 to 16)
This dose is unique to Wegovy and does not exist in the Ozempic escalation. It bridges the gap between 1.0 mg and the maintenance dose:
- Weight loss continues to accelerate for many patients
- Side effects from this increase tend to be milder than previous jumps because your body has had 12 weeks to adjust to semaglutide
- By now you have established new eating habits that complement the medication's effects
- Total weight loss by the end of this step is typically 12 to 18 pounds
Step 5: 2.4 mg Maintenance (Week 17+)
The full therapeutic dose. This is where the STEP trial results were measured:
- The STEP 1 trial showed an average of 14.9% body weight loss at 68 weeks at this dose[3]
- Appetite suppression is at its strongest
- Most patients report feeling genuinely satisfied on 1,000 to 1,500 calories per day without feeling deprived
- Weight loss continues for approximately 60 to 68 weeks before plateauing
- Side effects at the 2.4 mg dose are generally well-tolerated if you have followed the full titration
In the SELECT cardiovascular outcomes trial, adults with obesity and established cardiovascular disease who took semaglutide 2.4 mg once weekly experienced a 20% reduction in major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.80; 95% CI, 0.72 to 0.90)[4].
Side Effect Management by Dose
Side effects follow a predictable pattern. They tend to peak during the first week at each new dose and fade as your body adjusts:
| Side Effect | Frequency | Management |
|---|---|---|
| Nausea | ~44% of patients | Eat smaller meals, avoid greasy foods, ginger tea, stay upright after eating |
| Diarrhea | ~30% of patients | Stay hydrated, avoid high-fat meals, consider probiotics |
| Constipation | ~24% of patients | Increase fiber gradually, drink more water, consider a stool softener |
| Injection site reactions | ~3.5% of patients | Rotate injection sites, let alcohol swab dry fully, inject at room temperature |
| Fatigue | ~11% of patients | Usually temporary, ensure adequate calorie and protein intake |
If nausea is severe or does not improve after 2 weeks at a given dose, your provider may extend that dose step by an additional 4 weeks before escalating. There is no requirement to move to the next step on a fixed timeline.
Missed Dose Protocol
Wegovy is administered once weekly subcutaneously in the abdomen, thigh, or upper arm[1]. If you miss a dose, the FDA prescribing information specifies: administer it as soon as possible if the next scheduled dose is more than 48 hours away. If fewer than 48 hours remain until the next scheduled dose, skip the missed injection and resume your regular weekly schedule[1].
What If You Cannot Tolerate 2.4 mg?
Not every patient will reach or need the full 2.4 mg dose. Some patients achieve excellent results at 1.7 mg or even 1.0 mg. If the 2.4 mg dose causes persistent nausea or vomiting that does not improve after 4 to 8 weeks, your provider may recommend:
- Staying at 1.7 mg as your maintenance dose
- Trying the 2.4 mg dose again after a longer period at 1.7 mg
- Switching to a different medication if semaglutide is not well tolerated at any effective dose
The best dose is the one you can take consistently for the long term.
Compounded GLP-1 medications are not FDA-approved. While legal during FDA-recognized drug shortages, they do not undergo the same rigorous testing as brand-name drugs. Always verify your provider uses a licensed 503A or 503B compounding pharmacy.
Supply and Pen Information
Wegovy uses single-dose, prefilled pens[2]. Each box contains four pens (one month's supply at once-weekly dosing).
| Pen Strength | Needle Gauge | Injection Volume |
|---|---|---|
| 0.25 mg | 30-gauge | 0.5 mL |
| 0.5 mg | 30-gauge | 0.5 mL |
| 1.0 mg | 30-gauge | 0.5 mL |
| 1.7 mg | 30-gauge | 0.5 mL |
| 2.4 mg | 30-gauge | 0.5 mL |
All pens use the same 30-gauge needle, which is among the thinnest available. Most patients describe the injection as a brief pinch that lasts a few seconds.
Ready to start your weight loss journey? Find a GLP-1 clinic near you and connect with a qualified provider today.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.
Sources
- U.S. Food and Drug Administration. (2025). "WEGOVY (semaglutide) injection, for subcutaneous use, Full Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
- National Library of Medicine, DailyMed. (2025). "WEGOVY (semaglutide injection, solution)." https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Wilding, J.P.H., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 384, 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Lincoff, A.M., et al. (2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine, 389, 2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563